loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X

Approved Drug Products containing 78203 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Left Arrow
Right Arrow
Filters Filter
Cross PopUp
FILTER :

filter

01 LEADING (3)

filter

01 TABLET;ORAL (3)

filter

01 RX (3)

filter

01 LORAZEPAM (3)

filter

01 No (3)

URL Supplier Web Content
TABLET; ORAL
1MG
2007-07-30
78203
LORAZEPAM
RX
No
AB
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
TABLET; ORAL
2MG
2007-07-30
78203
LORAZEPAM
RX
No
AB
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
TABLET; ORAL
0.5MG
2007-07-30
78203
LORAZEPAM
RX
No
AB
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for FDA Orange Book APPLICATION 78203

Looking for FDA Orange Book APPLICATION 78203 3

19

Leading Pharma, LLC, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is LORAZEPAM, with a corresponding application number 78203.

Regulatory Information RX

With a dosage strength 1MG

Dosage Form Route TABLET; ORAL

Reference Listed Drug No

Approved since 2007-07-30

Therapeutic Equivalence (TE) Code AB

18

Leading Pharma, LLC, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is LORAZEPAM, with a corresponding application number 78203.

Regulatory Information RX

With a dosage strength 2MG

Dosage Form Route TABLET; ORAL

Reference Listed Drug No

Approved since 2007-07-30

Therapeutic Equivalence (TE) Code AB

17

Leading Pharma, LLC, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA.

One of their notable products is LORAZEPAM, with a corresponding application number 78203.

Regulatory Information RX

With a dosage strength 0.5MG

Dosage Form Route TABLET; ORAL

Reference Listed Drug No

Approved since 2007-07-30

Therapeutic Equivalence (TE) Code AB

Post Enquiry
POST ENQUIRY